KRAS and myelodysplastic syndrome: Therefore, the presence of mutations that interest the signaling genes (such as NRAS, KRAS, PTPN11, CBL, JAK2, FLT3) and IDH1 and IDH2 mutations could lead to the MDS’s progression into AML.